Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
Since the mean/median duration for each of these studies was 100,000 patients prescribed a GLP-1RA, after propensity matching, there was reduced risk for PDAC during a 5-year observation period for GLP-1RA users compared to six categories of commonly used diabetes medication classes 44
Peer-reviewed clinical trials Wilding JPH et al., STEP-1, NEJM 2021, PMID 33567185 : semaglutide 2,4 mg, weight loss -14,9% at 68 weeks
But here's the catch: retatrutide isn't approved yet
For most people, a healthy calorie deficit is around 300500 calories per day
ADA 2019 Oral SemaglutideThe PIONEER Program Trials